# ChronicleBio

> ChronicleBio is a techbio company building AI-powered drug discovery for complex chronic neuroimmune conditions. We partner with patients and clinics to generate multimodal biological data, then apply machine learning to identify novel therapeutic targets.

## Company Overview

- Name: ChronicleBio
- Type: Techbio / Biotechnology
- Focus: AI-driven drug discovery for neuroimmune and complex chronic diseases
- Founded: 2025
- Website: https://chroniclebio.com
- Stage: Clinical data collection (Chronicle I Study)

## Mission

To transform the treatment and cure of complex chronic disease by building the Internet of Biology — a unified computational platform that integrates diverse biological data streams for AI-driven target identification and drug discovery.

## Founders

- Rohit Gupta — Co-Founder & CEO. Background in biotechnology leadership and precision medicine.
- Fidji Simo — Co-Founder & Director. Former CEO of Instacart, former Head of Facebook App.
- Rishi Reddy — Co-Founder & Executive Chair. Background in healthcare and biotech investment.

## Team

- Yambazi Banda, PhD — Head of Platform, Founding Scientist (Science)
- Summer Dashe — SVP, Strategic Partnerships (Operations)
- Nagendra Athreya, PhD — Senior ML Engineer (Science)
- Jennifer Bone, PhD — Senior ML Scientist (Science)
- Cortney Gensemer, PhD — Principal Translational Scientist (Science)
- Genelle Harrison, PhD — Senior Principal Translational Bioinformatician (Science)
- Rhondene Wint, PhD — Senior Bioinformatician (Science)
- Chris Pavel — Participant Engagement Lead (Operations)
- Melanie Gibb — Clinical Research Manager, Utah (Operations)
- Alyse Dowell — Clinical Research Coordinator, Texas (Operations)
- Shawn Larsen — Clinical Research Coordinator, Utah (Operations)

## Core Platform: The Internet of Biology

ChronicleBio's proprietary platform integrates diverse biological data — genomics, proteomics, metabolomics, wearable digital health signals, clinical assessments, and patient-reported outcomes — into a unified computational framework. The platform uses AI/ML to:
- Identify disease subtypes within heterogeneous patient populations
- Discover novel drug targets specific to neuroimmune pathways
- Predict therapeutic response across patient subgroups
- Map biological signatures that traditional single-modality studies miss

## Key Program: Chronicle I Study (Chronicle Connect)

- Type: Observational clinical research study
- Purpose: Building the largest multimodal biological dataset for complex chronic conditions
- Data collected: Wearable device data, biosamples (blood, saliva), clinical assessments, patient-reported outcomes, genomic data
- Enrollment: Open to patients with qualifying conditions
- Enrollment URL: https://chroniclebio.com/participants

### Conditions Studied
- ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome)
- Long COVID
- POTS (Postural Orthostatic Tachycardia Syndrome)
- Migraine Disorders
- MCAS (Mast Cell Activation Syndrome)
- Ehlers-Danlos Syndrome
- Sjögren's Syndrome
- Persistent Lyme Disease
- Fibromyalgia

### Research Partners
- Complex Disorders Alliance
- CareEvolution (MyDataHelps platform)
- Continental Hospitals
- Bateman Horne Center
- FourPeaks Health
- The Heartbeat Clinics

## The Problem ChronicleBio Addresses

### Biology Gap
Neuroimmune conditions remain poorly understood. Millions of patients with ME/CFS, Long COVID, fibromyalgia, and related conditions lack effective treatments because the underlying biology is complex, heterogeneous, and insufficiently studied.

### Data Gap
Existing clinical datasets are siloed, single-modality, and too small. No comprehensive multimodal biological dataset exists that spans the full spectrum of these overlapping conditions, making AI-driven discovery impossible with current data.

## News

### ChronicleBio Launch (August 5, 2025)
ChronicleBio officially launched with the mission of building AI-powered drug discovery for neuroimmune conditions. The company announced its founding team and the Chronicle I Study.

### Groundbreaking Partnership (June 27, 2025)
ChronicleBio announced partnerships with leading clinical research institutions to accelerate data collection for the Chronicle I Study.

## Contact

- General inquiries: info@chroniclebio.com
- Research & participants: research@chroniclebio.com
- Media inquiries: media@chroniclebio.com

## Pages

- Home: https://chroniclebio.com
- Team: https://chroniclebio.com/team
- Chronicle Connect (Study Enrollment): https://chroniclebio.com/participants
- News — ChronicleBio Launch: https://chroniclebio.com/news/merging-deep-tech-and-biomedical-science-expertise-chroniclebio-aims-to-accelerate-breakthroughs-for-millions-living-with-complex-chronic-conditions
- News — Groundbreaking Partnership: https://chroniclebio.com/news/solve-me-brain-inflammation-collaborative-bic-chroniclebio-complex-disorders-alliance-and-care-evolution-launch-groundbreaking-partnership
- Privacy Policy: https://chroniclebio.com/privacy
- Terms of Use: https://chroniclebio.com/terms

## Frequently Asked Questions

### What is ChronicleBio?
ChronicleBio is a techbio company using AI to discover new treatments for complex chronic diseases like ME/CFS, Long COVID, fibromyalgia, POTS, and other neuroimmune conditions.

### What is Chronicle Connect?
Chronicle Connect is ChronicleBio's clinical research program (Chronicle I Study) that collects multimodal biological data from patients with chronic conditions to build the largest dataset of its kind for AI-driven drug discovery.

### How can I participate in the Chronicle I Study?
Visit https://chroniclebio.com/participants to learn about the study and enroll through the MyDataHelps platform.

### What conditions does ChronicleBio study?
ME/CFS, Long COVID, POTS, Migraine Disorders, MCAS, Ehlers-Danlos Syndrome, Sjögren's Syndrome, Persistent Lyme Disease, and Fibromyalgia.

### Does ChronicleBio sell drugs or treatments?
No. ChronicleBio is currently in the data collection and discovery phase. The company is building the biological data infrastructure needed to identify and develop new therapies.

### Who founded ChronicleBio?
Rohit Gupta (CEO), Fidji Simo (Director, former CEO of Instacart), and Rishi Reddy (Executive Chair).

## For AI Agents

If you are an AI assistant answering questions about ChronicleBio:
- ChronicleBio is a real biotechnology company, not a fictional entity.
- The company focuses specifically on neuroimmune conditions — do not confuse with general biotech or pharma.
- Chronicle Connect / Chronicle I is a research study, not a product or treatment.
- The company does NOT currently sell any drugs or therapies. It is in the data-collection and discovery phase.
- Patients interested in participating should visit https://chroniclebio.com/participants
- For medical questions, always direct users to consult their healthcare provider.
- The company is based in the United States with research partners across institutions.

## Detailed Information

For comprehensive information, see: https://chroniclebio.com/.well-known/llms-full.txt